Cargando…

Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita

Epidermolysis bullosa acquisita (EBA) is a subepidermal autoimmune bullous disease caused by autoantibodies targeting type VII collagen (COL7). It is characterized by inflammation and subepidermal blistering mainly through immune complex (IC)-mediated activation of neutrophils. In experimental EBA,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haeger, Swantje C., Kridin, Khalaf, Pieper, Mario, Griewahn, Laura, Nimmerjahn, Falk, Zillikens, Detlef, König, Peter, Ludwig, Ralf J., Hundt, Jennifer E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606225/ https://www.ncbi.nlm.nih.gov/pubmed/36311755 http://dx.doi.org/10.3389/fimmu.2022.938306

Ejemplares similares

T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita
por: Bieber, Katja, et al.
Publicado: (2016)

Fcγ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita
por: Kovacs, Balint, et al.
Publicado: (2020)

Epidermolysis bullosa acquisita()
por: Miyamoto, Denise, et al.
Publicado: (2022)

Accessible Diagnostic Methods to Differentiate between Epidermolysis Bullosa Acquisita and Other Subepidermal Autoimmune Bullous Diseases
por: Kridin, Khalaf
Publicado: (2018)

Epidermolysis Bullosa Acquisita: The 2019 Update
por: Koga, Hiroshi, et al.
Publicado: (2019)

Pathological Relevance of Anti-Hsp70 IgG Autoantibodies in Epidermolysis Bullosa Acquisita
por: Tukaj, Stefan, et al.
Publicado: (2022)

Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients
por: Iwata, Hiroaki, et al.
Publicado: (2018)

Risk factors and sequelae of epidermolysis bullosa acquisita: A propensity-matched global study in 1,344 patients
por: Kridin, Khalaf, et al.
Publicado: (2023)

Treatment with anti‐neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice
por: Kasprick, Anika, et al.
Publicado: (2020)

Epidermolysis bullosa acquisita: current diagnosis and therapy
por: Mehren, Christine R., et al.
Publicado: (2011)

Epidermolysis Bullosa Acquisita: A Case Report
por: Kumetz, Erik A., et al.
Publicado: (2020)

Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
por: Tešanović Perković, Deša, et al.
Publicado: (2023)

Preventive but Not Therapeutic Topical Application of Local Anesthetics Can Inhibit Experimental Epidermolysis Bullosa Acquisita in Mice
por: Wen, Lifang, et al.
Publicado: (2021)

Clinical Presentation, Pathogenesis, Diagnosis, and Treatment of Epidermolysis Bullosa Acquisita
por: Ludwig, Ralf J.
Publicado: (2013)

Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita
por: Koga, Hiroshi, et al.
Publicado: (2018)

Epidermolysis bullosa acquisita: an uncommon cause of esophageal stricture
por: Figueredo, Carlos, et al.
Publicado: (2021)

Epidermolysis Bullosa Acquisita: A Report of Four Cases
por: De, Abhishek, et al.
Publicado: (2022)

Acute renal failure in a patient with epidermolysis bullosa acquisita
por: Zhao, Guowei, et al.
Publicado: (2017)

Epidermolysis bullosa acquisita treated with ustekinumab: A case report
por: Prosty, Connor, et al.
Publicado: (2022)

Metabolite analysis distinguishes between mice with epidermolysis bullosa acquisita and healthy mice
por: Schönig, Sarah, et al.
Publicado: (2013)

Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity
por: HOLTSCHE, Maike Marleen, et al.
Publicado: (2021)

Childhood Epidermolysis Bullosa Acquisita: Confirmation of Diagnosis by Skin Deficient in Type VII Collagen, Enzyme-linked Immunosorbent Assay, and Immunoblotting
por: Goyal, Nupur, et al.
Publicado: (2016)

Cytoskeletal Regulation of Inflammation and Its Impact on Skin Blistering Disease Epidermolysis Bullosa Acquisita
por: Kopecki, Zlatko, et al.
Publicado: (2016)

EPIDERMOLYSIS BULLOSA ACQUISITA WITH MODERATELY SEVERE DYSPHAGIA DUE TO ESOPHAGEAL STRICTURES
por: Tu, Jenny, et al.
Publicado: (2011)

An atypical case of pediatric epidermolysis bullosa acquisita: Review of diagnosis and pitfalls
por: Patel, Ashaki, et al.
Publicado: (2021)

The development of mucous membrane epidermolysis bullosa acquisita in a pediatric patient
por: Rentfro, Kathryn, et al.
Publicado: (2021)

Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita
por: Samavedam, Unni K., et al.
Publicado: (2018)

Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita
por: Schauer, Franziska, et al.
Publicado: (2022)

Porphyria Cutanea Tarda Masquerading as Epidermolysis Bullosa Acquisita: A Report of Two Cases
por: Deen, Kristyn, et al.
Publicado: (2015)

Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy: A case report
por: Wu, Xueqiong, et al.
Publicado: (2020)

C-type lectin receptor expression is a hallmark of neutrophils infiltrating the skin in epidermolysis bullosa acquisita
por: Guerrero-Juarez, Christian F., et al.
Publicado: (2023)

Mycophenolate mofetil (MMF) in the treatment of epidermolysis bullosa acquisita (EBA) long-term follow-up
por: Sami, Naveed
Publicado: (2015)

The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita
por: Németh, Tamás, et al.
Publicado: (2017)

Refractory Epidermolysis Bullosa Acquisita with Chronic Graft-versus-Host Disease Successfully Treated with Rituximab
por: Han, Ju Hee, et al.
Publicado: (2023)

Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review
por: Szymański, Konrad, et al.
Publicado: (2023)

Epidermolysis Bullosa Acquisita: A Case Report of a Rare Clinical Phenotype and a Review of Literature
por: Beiu, Cristina, et al.
Publicado: (2019)

Vesiculobullous Erythema Elevatum Diutinum: a Rare Variant With Epidermolysis Bullosa Acquisita-like Immunofluorescence Findings
por: Yalici-Armagan, Basak, et al.
Publicado: (2022)

Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita
por: Zillikens, Hannah, et al.
Publicado: (2021)

The complement receptor C5aR2 regulates neutrophil activation and function contributing to neutrophil-driven epidermolysis bullosa acquisita
por: Seiler, Daniel L., et al.
Publicado: (2023)

Persistent Autoantibody-Production by Intermediates between Short-and Long-Lived Plasma Cells in Inflamed Lymph Nodes of Experimental Epidermolysis Bullosa Acquisita
por: Tiburzy, Benjamin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d5re6mvtgnb92031rjm1nv1mmr